Skip to main content
. 2020 Jun 27;43(10):1045–1055. doi: 10.1007/s40264-020-00964-x

Table 3.

Subject demographics of the onapristone extended release (ONA-ER) pooled safety analysis (n = 88)

Demographic n (%)
Female 52 (59.1)
Male 36 (40.9)
Age, median (range) 68.0 (36–89)
 > 65 years 61 (69.3)
Ethnicity
 African ancestry 0 (0)
 Asian 0 (0)
 Caucasian 87 (98.9)
 Unknown 1 (0.9)
Tumor type
 Endometrial/uterine 19 (21.5)
 Ovarian 12 (13.6)
 Breast 21 (23.9)
 Prostate 36 (41.0)
Metastases
 Liver 25 (28.4)
 Bone 42 (47.7)
Treatment
 ONA-ER 73 (83.0)
 ONA-ER+ abiraterone 15 (17.0)